Kazia Therapeutics: Completes recruitment for ongoing paxalisib phase 2 study
- Kazia Therapeutics has also completed the recruitment stage for its phase two study for paxalisib
- Paxalisib is its lead drug candidate for treating glioblastoma, the world’s most aggressive form of cancer
- Then the company started a phase two clinical trial in glioblastoma in 2018
- In May 2019, Kazia reported a maximum tolerated dose of 60 milligrams determined for the newly-diagnosed population
- Aside from this phase two glioblastoma study, Kazia is also conducting four other studies in other forms of cancer
- Kazia’s shares are flat on the market and trading for 64 cents each at market close
